Picard Medical Showcases Fully Implantable Emperor System and Enhanced Recovery Data
Picard Medical’s clinical VP will deliver three presentations at the March 2–4 THT conference, covering preclinical in vitro and in vivo data for the fully implantable Emperor system and updated registry analyses for the SynCardia Total Artificial Heart. Data show Emperor preserves physiological performance while eliminating transdermal drivelines, and registry results demonstrate organ recovery and enhanced quality-of-life outcomes.
1. Conference Presentations
Picard Medical’s Dr. Andre Simon will deliver three presentations at THT 2026 in Boston from March 2 to 4, focusing on both the SynCardia Total Artificial Heart and the next-generation fully implantable Emperor system. Sessions include a scientific abstract on the Emperor’s first in vitro and in vivo evaluation, an educational lecture on future therapy priorities, and a clinical outcomes presentation.
2. Emperor System Preclinical Progress
Early laboratory and preclinical data demonstrate that the Emperor system preserves the proven physiologic performance of the SynCardia Total Artificial Heart while eliminating transdermal pneumatic drivelines. This fully implantable design aims to boost patient mobility, quality of life, and long-term independence.
3. Enhanced Patient Outcomes Data
Updated registry analyses for the SynCardia Total Artificial Heart highlight outcomes beyond survival, such as organ recovery, functional improvement for early implants, and preserved transplant eligibility even in initially ineligible patients. Renal and neurological outcomes emerge as key determinants of long-term success, underscoring quality-of-life gains after early postoperative recovery.